Patents Examined by Jeffrey H Murray
  • Patent number: 11819476
    Abstract: The present invention provides compounds of formula I, compositions thereof, and methods of using the same as mTORC1 inhibitors.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: November 21, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: David John O'Neill, Eddine Saiah, Seong Woo Anthony Kang
  • Patent number: 11814380
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg, Marco Hans Hofmann, Anke Baum, Michael Gmachl, Dorothea Ingrid Rudolph, Fabio Savarese, Markus Ostermeier, Markus Frank, Annika Gille, Stefan Goepper, Marco Santagostino, Julian Wippich
  • Patent number: 11814392
    Abstract: Chromenopyridine-based compounds are provided. In one aspect, the present disclosure provides a method for treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of a chromenopyridine-based compound to the subject. A representative compound is 2,4-diamino-7,8-dimethoxy-5-((4-methoxyphenyl)thio)-5H-chromeno[2,3-b]pyridine-3-carbonitrile (Compound 1).
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: November 14, 2023
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventors: June A Mayor, Shivaputra A. Patil, Ronald S. Kaplan
  • Patent number: 11795162
    Abstract: In one aspect, the present disclosure describes new estrogen receptor-related orphan receptor (EER) inverse agonist compounds. Also described are pharmaceutical formulations, methods of synthesis and uses thereof.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: October 24, 2023
    Assignee: Saint Louis University
    Inventors: Thomas Burris, John K. Walker, Carissa S. Hampton, Keith McCormick Haynes, Kristine Griffett, Cyrielle Billon, Sadichha Sitaula
  • Patent number: 11793823
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC?OR6, (C?O)R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: October 24, 2023
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
  • Patent number: 11771697
    Abstract: The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by proteins of the SWI/SNF chromatin-remodeling complex, including PB1.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 3, 2023
    Inventors: Eric Fischer, Nathanael Gray, Radoslaw Nowak, Katherine Donovan, Tinghu Zhang, Yao Liu
  • Patent number: 11773080
    Abstract: The invention provides deuterium-enriched isoindolinonyl-azepanediones, deuterium-enriched oxoquinazolin-3(4H)-yl-azepanediones, related compounds, pharmaceutical compositions, and methods of using such compounds and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 3, 2023
    Assignee: Salarius Pharmaceuticals, Inc.
    Inventors: Sheila DeWitt, Vincent Jacques
  • Patent number: 11753407
    Abstract: Provided herein are compounds of Formula (I): and forms thereof, wherein w1, w2, w3, w4, w5, w6 and w7 are as defined herein, including compositions thereof and uses therewith for treating spinal muscular atrophy.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: September 12, 2023
    Assignees: PTC Therapeutics, Inc., F. Hoffmann-La Roche AG
    Inventors: Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Yurpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
  • Patent number: 11737463
    Abstract: The present invention relates to compounds of formula I wherein the variables are defined as given in the description and claims. The invention further relates to uses and composition for compounds of formula I.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: August 29, 2023
    Assignee: BASF SE
    Inventors: Bernd Mueller, Ana Escribano Cuesta, Michael Seet, Antje Wolf, Nadine Riediger, Marcus Fehr, Erica Cambeis, Jan Klaas Lohmann, Thomas Grote, Wassilios Grammenos, Christian Harald Winter, Violeta Terteryan-Seiser
  • Patent number: 11738008
    Abstract: A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.
    Type: Grant
    Filed: February 9, 2019
    Date of Patent: August 29, 2023
    Assignee: Emory University
    Inventors: Dennis Liotta, Stephen F. Traynelis, David Menaldino, Matthew Epplin
  • Patent number: 11738019
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 29, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph Panarese, Samuel Bartlett, Dexter Davis, Nathaniel Kenton, Yat Sun Or
  • Patent number: 11717522
    Abstract: The present invention relates to a method for preparing a lyophilized solid pharmaceutical composition comprising a) a compound having the formula (I): and/or a compound having the formula (II): ?and b) two different sodium phosphate salts, wherein the two different sodium phosphate salts are NaH2PO4·2H2O and Na2HPO4·2H2O, and wherein the quantity of the NaH2PO4·2H2O and Na2HPO4·2H2O present in the composition is chosen such that the molar ratio of both NaH2PO4·2H2O and Na2HPO4·2H2O to compound (I) or compound (II) ranges from 0.02 to 0.5.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: August 8, 2023
    Assignee: VASOPHARM GMBH
    Inventors: Peter Scheurer, Frank Tegtmeier, Reinhard Schinzel
  • Patent number: 11714072
    Abstract: A reagent composition for a Karl Fischer titration includes (1) sulfur dioxide or a derivative thereof, (2) a derivative of imidazole, (3) an alcohol, and (4) at least one amino acid that is present in an amount that is greater than zero and up to about 10 weight percent based on a total weight of the reagent composition. Moreover, a molar ratio of the derivative of imidazole to the sulfur dioxide or derivative thereof is greater than 1:1. Iodine is optionally included in a one-component reagent and excluded in a two-component reagent. This disclosure further provides a method for determining an amount of water in a sample via Karl Fischer titration. The method includes the step of providing the sample, providing the reagent composition, which optionally includes the iodine (I2), and titrating the sample with the reagent composition.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: August 1, 2023
    Inventors: Stefan Seekamp, Marco Konopatzki
  • Patent number: 11702399
    Abstract: Disclosed are a quinazolinone derivative, a preparation method therefor, a pharmaceutical composition, and applications. Provided are a compound represented by formula I, a pharmaceutically acceptable salt, a solvate, a crystal form, a eutectic crystal, a stereoisomer, an isotope compound, a metabolite, or a prodrug thereof. Generation or activity of a cell factor can be regulated, and accordingly, cancers and inflammatory diseases can be effectively treated.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: July 18, 2023
    Assignee: Kangpu Biopharmaceuticals, Ltd.
    Inventors: Wen-Cherng Lee, Baisong Liao
  • Patent number: 11691988
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: July 4, 2023
    Assignee: Kancera AB
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Patent number: 11690844
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: July 4, 2023
    Assignee: Purdue Research Foundation
    Inventors: Daniel P. Flaherty, Richard M. van Rijn, Val J. Watts, Jason A. Scott
  • Patent number: 11679107
    Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 20, 2023
    Inventors: Andrew Cook, Dominic Reynolds, Cheng Zhong, Ryan Brawn, Shelby Ellery, Thiwanka Samarakoon, Xiang Liu, Sudeep Prajapati, Megan Sheehan, Jason T. Lowe, James Palacino
  • Patent number: 11680067
    Abstract: Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: June 20, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventor: Jean X. Jiang
  • Patent number: 11673898
    Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: June 13, 2023
    Inventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
  • Patent number: 11661401
    Abstract: The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: May 30, 2023
    Inventors: Elena S. Koltun, Kevin Mellem, Adrian Gill, Gert Kiss, Christopher Semko, Naing Aay, Andreas Buckl, Ashutosh Jogalekar, Walter Won